Immunity to HIV in early life

Frontiers in Immunology

Volumn 5, Issue AUG, 2014, Pages

  Muenchhoff, Maximilian ^a   Prendergast J , Andrew ^b,c   Goulder, Philip Jeremy Renshaw ^a,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c Zvitambo Institute for Maternal and Child Health Research   (Zimbabwe)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Adaptive immunity; HIV; Immune activation; Immune exhaustion; Immune responses; Innate immunity; Pediatric; Viral reservoir

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOKINE; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DNA POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INNATE IMMUNITY; META ANALYSIS (TOPIC); NATURAL KILLER CELL; NONHUMAN; REGULATORY T LYMPHOCYTE; SIMIAN IMMUNODEFICIENCY VIRUS; SURVIVAL TIME; TH17 CELL; TH2 CELL; VERTICAL TRANSMISSION; VIRUS LOAD;

EID: 84915760045     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00391     Document Type: Article

References (202)

1. Prendergast AJ, Klenerman P, Goulder PJ. The impact of differential antivi-ral immunity in children and adults. Nat Rev Immunol (2012) 12(9):636-48. doi:10.1038/nri3277
2. Brenchley JM. Mucosal immunity in human and simian immunodeficiency lentivirus infections. Mucosal Immunol (2013) 6(4):657-65. doi:10.1038/mi. 2013.15
3. Khaitan A, Unutmaz D. Revisiting immune exhaustion during HIV infection. Curr HIV/AIDS Rep (2011) 8(1):4-11. doi:10.1007/s11904-010-0066-0
4. Paiardini M, Muller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev (2013) 254(1):78-101. doi:10.1111/imr.12079
5. PersaudD,GayH,Ziemniak C,ChenYH, PiatakMJr.,Chun TW, et al.Absence of detectableHIV-1 viremia after treatment cessation in an infant.NEngl JMed (2013) 369(19):1828-35. doi:10.1056/NEJMoa1302976
6. Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev (2011) (7):CD003510. doi:10.1002/14651858.CD003510. pub3
7. World Health Organisation. Consolidated Guidelines on the Use of Antiretro-viral Drugs for Treating and Preventing HIV Infection. (2013). Available from: http://wwwwhoint/hiv/pub/guidelines/arv2013/en/
8. Working Group on Mother-to-Child Transmission of HIV. Rates of mother-to-child transmission of HIV-1 in Africa, America and Europe: results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 8:506-10. doi:10.1097/00042560-199504120-00011
9. Chahroudi A, Meeker T, Lawson B, Ratcliffe S, Else J, Silvestri G. Mother-to-infant transmission of simian immunodeficiency virus is rare in sooty mangabeys and is associated with low viremia. J Virol (2011) 85(12):5757-63. doi:10.1128/JVI.02690-10
10. AmedeeAM,Rychert J, LacourN, Fresh L,RatterreeM.Viral and immunologi-cal factors associated with breastmilk transmission of SIV in rhesusmacaques. Retrovirology (2004) 1:17. doi:10.1186/1742-4690-1-17
11. Pandrea I, Onanga R, Souquiere S, Mouinga-Ondeme A, Bourry O, Makuwa M, et al. Paucity of CD4+ CCR5+ T cells may prevent transmission of simian immunodeficiency virus in natural nonhuman primate hosts by breast-feeding. J Virol (2008) 82(11):5501-9. doi:10.1128/JVI.02555-07
12. van't Wout AB, Kootstra NA, Mulder-Kampinga GA, Albrecht-van Lent N, Scherpbier HJ, Veenstra J, et al. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest (1994) 94(5):2060-7. doi:10.1172/JCI117560
13. Chahroudi A, Cartwright E, Lee ST, Mavigner M, Carnathan DG, Lawson B, et al. Target cell availability, rather than breast milk factors, dictates mother-to-infant transmission of SIV in sooty mangabeys and rhesus macaques. PLoS Pathog (2014) 10(3):e1003958. doi:10.1371/journal.ppat.1003958
14. Shalekoff S, Gray GE, Tiemessen CT. Age-related changes in expression of CXCR4 and CCR5 on peripheral blood leukocytes from uninfected infants born to human immunodeficiency virus type 1-infected mothers. Clin Diagn Lab Immunol (2004) 11(1):229-34. doi:10.1128/CDLI.11.1.229
15. Bunders MJ, van der Loos CM, Klarenbeek PL, van Hamme JL, Boer K,Wilde JC, et al. Memory CD4(+)CCR5(+) T cells are abundantly present in the gut of newborn infants to facilitate mother-to-child transmission of HIV-1. Blood (2012) 120(22):4383-90. doi:10.1182/blood-2012-06-437566
16. Babiker A, Darby S, De Angelis D, Ewart D, Porter K, Beral V, et al. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet (2000) 355(9210):1131-7. doi:10.1016/S0140-6736(00)02061-4
17. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet (2004) 364(9441):1236-43. doi:10.1016/S0140-6736(04)17140-7
18. Becquet R, Marston M, Dabis F, Moulton LH, Gray G, Coovadia HM, et al. Children who acquireHIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis. PLoS One (2012) 7(2):e28510. doi:10.1371/journal.pone.0028510
19. Marinda E, Humphrey JH, Iliff PJ, Mutasa K, Nathoo KJ, Piwoz EG, et al. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis J (2007) 26(6):519-26. doi:10.1097/01.inf.0000264527. 69954.4c
20. MarstonM,BecquetR,Zaba B,Moulton LH,GrayG,CoovadiaH, et al.Net sur-vival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa. Int J Epidemiol (2011) 40(2):385-96. doi:10.1093/ije/dyq255
21. Ferrand RA, Corbett EL,Wood R, Hargrove J, Ndhlovu CE, Cowan FM, et al. AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS (2009) 23(15):2039-46. doi:10.1097/QAD.0b013e32833016ce
22. Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm ER, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol (2003) 112(5):973-80. doi:10.1016/j.jaci.2003.07.003
23. Schatorje EJ, Gemen EF, Driessen GJ, Leuvenink J, van Hout RW, de Vries E. Paediatric reference values for the peripheral T cell compartment. Scand J Immunol (2012) 75(4):436-44. doi:10.1111/j.1365-3083.2012.02671.x
24. European Collaborative S. Level and pattern of HIV-1-RNA viral load over age: differences between girls and boys? AIDS (2002) 16(1):97-104. doi:10. 1097/00002030-200201040-00012
25. MphatsweW, Blanckenberg N, Tudor-Williams G, Prendergast A, Thobakgale C,Mkhwanazi N, et al. High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. AIDS (2007) 21(10):1253-61. doi:10.1097/QAD.0b013e3281a3bec2
26. Obimbo EM, Wamalwa D, Richardson B, Mbori-Ngacha D, Overbaugh J, Emery S, et al. PediatricHIV-1 inKenya: pattern and correlates of viral load and association with mortality. J Acquir Immune Defic Syndr (2009) 51(2):209-15. doi:10.1097/QAI.0b013e31819c16d8
27. Biggar RJ, JanesM,Pilon R,Miotti P,Taha TE,Broadhead R, et al.Virus levels in untreated African infants infected with human immunodeficiency virus type 1. J Infect Dis (1999) 180(6):1838-43. doi:10.1086/315122
28. LylesRH,MunozA,YamashitaTE,BazmiH,DetelsR,RinaldoCR, et al.Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men.Multicenter AIDS Cohort Study. J Infect Dis (2000) 181(3):872-80. doi:10.1086/315339
29. Saathoff E, Pritsch M, Geldmacher C, Hoffmann O, Koehler RN, Maboko L, et al. Viral and host factors associated with the HIV-1 viral load setpoint in adults from Mbeya Region, Tanzania. J Acquir Immune Defic Syndr (2010) 54(3):324-30. doi:10.1097/QAI.0b013e3181cf30ba
30. McIntosh K, Shevitz A, Zaknun D, Kornegay J, Chatis P, Karthas N, et al. Age-and time-related changes in extracellular viral load in children verti-cally infected by human immunodeficiency virus. Pediatr Infect Dis J (1996) 15(12):1087-91. doi:10.1097/00006454-199612000-00006
31. Rustagi A, Gale M Jr. Innate antiviral immune signaling, viral evasion and modulation by HIV-1. J Mol Biol (2014) 426(6):1161-77. doi:10.1016/j.jmb. 2013.12.003
32. Stetson DB,Medzhitov R. Type I interferons in host defense. Immunity (2006) 25(3):373-81. doi:10.1016/j.immuni.2006.08.007
33. Zhang SY, Jouanguy E, Ugolini S, Smahi A, Elain G, Romero P, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science (2007) 317(5844):1522-7. doi:10.1126/science.1139522
34. Ricci E, Malacrida S, Zanchetta M, Mosconi I, Montagna M, Giaquinto C, et al. Toll-like receptor 9 polymorphisms influence mother-to-child transmis-sion of human immunodeficiency virus type 1. J Transl Med (2010) 8:49. doi:10.1186/1479-5876-8-49
35. Qin M, Brummel S, Singh KK, Fenton T, Spector SA. Associations of host genetic variants on CD4+ lymphocyte count and plasma HIV-1 RNA in antiretroviral naive children. Pediatr Infect Dis J (2014). doi:10.1097/INF. 0000000000000330
36. Bunupuradah T, ImahashiM, Iampornsin T,MatsuokaK, IwataniY,Puthanakit T, et al. Association of APOBEC3G genotypes and CD4 decline in Thai and Cambodian HIV-infected children with moderate immune deficiency. AIDS Res Ther (2012) 9(1):34. doi:10.1186/1742-6405-9-34
37. Singh KK, Wang Y, Gray KP, Farhad M, Brummel S, Fenton T, et al. Genetic variants in the host restriction factor APOBEC3G are associated with HIV-1-related disease progression and central nervous system impairment in chil-dren. J Acquir Immune Defic Syndr (2013) 62(2):197-203. doi:10.1097/QAI. 0b013e31827ab612
38. Kollmann TR, Crabtree J, Rein-Weston A, Blimkie D, Thommai F, Wang XY, et al.Neonatal innateTLR-mediated responses are distinct fromthose of adults. J Immunol (2009) 183(11):7150-60. doi:10.4049/jimmunol.0901481
39. Belderbos ME, van Bleek GM, Levy O, Blanken MO, Houben ML, Schuijff L, et al. Skewed pattern of Toll-like receptor 4-mediated cytokine production in human neonatal blood: low LPS-induced IL-12p70 and high IL-10 per-sist throughout the first month of life. Clin Immunol (2009) 133(2):228-37. doi:10.1016/j.clim.2009.07.003
40. Levy O. Innate immunity of the newborn: basic mechanisms and clinical cor-relates. Nat Rev Immunol (2007) 7(5):379-90. doi:10.1038/nri2075
41. Reikie BA, Adams RC, Leligdowicz A, Ho K, Naidoo S, Ruck CE, et al. Altered innate immune development in HIV-exposed uninfected infants. J Acquir Immune Defic Syndr (2014) 66(3):245-55. doi:10.1097/QAI. 0000000000000161
42. Miller E, Bhardwaj N. Dendritic cell dysregulation during HIV-1 infection. Immunol Rev (2013) 254(1):170-89. doi:10.1111/imr.12082
43. Selvaraj A, Pilakka-Kanthikeel S, Bhavani PK, Hanna LE, Pahwa S, Swami-nathan S. Defective dendritic cell response to Toll-like receptor 7/8 ago-nists in perinatally HIV-infected children. Pathogens Dis (2013) 69(3):184-93. doi:10.1111/2049-632X.12067
44. Usuga X, Montoya CJ, Landay AL, Rugeles MT. Characterization of quantitative and functional innate immune parameters in HIV-1-infected Colombian children receiving stable highly active antiretroviral ther-apy. J Acquir Immune Defic Syndr (2008) 49(4):348-57. doi:10.1097/QAI. 0b013e31818c16ff
45. Azzoni L, Rutstein RM, Chehimi J, Farabaugh MA, Nowmos A, Montaner LJ. Dendritic and natural killer cell subsets associated with stable or declin-ing CD4+ cell counts in treated HIV-1-infected children. J Infect Dis (2005) 191(9):1451-9. doi:10.1086/429300
46. Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annu Rev Immunol (2013) 31:163-94. doi:10.1146/annurev-immunol-032712-100001
47. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol (2002) 20:217-51. doi:10.1146/ annurev.immunol.20.092501.134942
48. Nakazawa T, Agematsu K, Yabuhara A. Later development of Fas ligand-mediated cytotoxicity as compared with granule-mediated cytotoxicity dur-ing the maturation of natural killer cells. Immunology (1997) 92(2):180-7. doi:10.1046/j.1365-2567.1997.00343.x
49. Sundstrom Y, Nilsson C, Lilja G, Karre K, Troye-Blomberg M, Berg L. The expression of human natural killer cell receptors in early life. Scand J Immunol (2007) 66(2-3):335-44. doi:10.1111/j.1365-3083.2007.01980.x
50. Yabuhara A, Kawai H, Komiyama A. Development of natural killer cytotoxicity during childhood:marked increases in number of natural killer cells with ade-quate cytotoxic abilities during infancy to early childhood. Pediatr Res (1990) 28(4):316-22. doi:10.1203/00006450-199010000-00002
51. Dalle JH, Menezes J, Wagner E, Blagdon M, Champagne J, Champagne MA, et al. Characterization of cord blood natural killer cells: implications for trans-plantation and neonatal infections. Pediatr Res (2005) 57(5 Pt 1):649-55. doi:10.1203/01.PDR.0000156501.55431.20
52. Guilmot A, Hermann E, Braud VM, Carlier Y, Truyens C. Natural killer cell responses to infections in early life. J Innate Immun (2011) 3(3):280-8. doi:10.1159/000323934
53. Ballan WM, Vu BA, Long BR, Loo CP, Michaelsson J, Barbour JD, et al. Nat-ural killer cells in perinatally HIV-1-infected children exhibit less degranu-lation compared to HIV-1-exposed uninfected children and their expression of KIR2DL3, NKG2C, and NKp46 correlates with disease severity. J Immunol (2007) 179(5):3362-70. doi:10.4049/jimmunol.179.5.3362
54. Ziegner U, Campbell D, Weinhold K, Frank I, Rutstein R, Starr SE. Deficient antibody-dependent cellular cytotoxicity against human immunodeficiency virus (HIV)-expressing target cells in perinatal HIV infection. Clin Diagn Lab Immunol (1999) 6(5):718-24.
55. Bernstein HB, Kinter AL, Jackson R, Fauci AS. Neonatal natural killer cells produce chemokines and suppress HIV replication in vitro. AIDS Res Hum Retroviruses (2004) 20(11):1189-95. doi:10.1089/0889222042544983
56. Slyker JA, Lohman-Payne B, John-StewartGC,Dong T,Mbori-NgachaD,Tapia K, et al. The impact of HIV-1 infection and exposure on natural killer (NK) cell phenotype in Kenyan infants during the first year of life. Front Immunol (2012) 3:399. doi:10.3389/fimmu.2012.00399
57. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine inter-actions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today (1993) 14(7):353-6. doi:10.1016/0167-5699(93)90235-D
58. Pazos M, Sperling RS, Moran TM, Kraus TA. The influence of pregnancy on systemic immunity. Immunol Res (2012) 54(1-3):254-61. doi:10.1007/s12026-012-8303-9
59. KourtisAP,Read JS, JamiesonDJ. Pregnancy and infection.NEngl JMed (2014) 370(23):2211-8. doi:10.1056/NEJMra1213566
60. Sperling RS, Engel SM, Wallenstein S, Kraus TA, Garrido J, Singh T, et al. Immunogenicity of trivalent inactivated influenza vaccination received during pregnancy or postpartum. Obstet Gynecol (2012) 119(3):631-9. doi:10.1097/ AOG.0b013e318244ed20
61. Ohfuji S, FukushimaW,DeguchiM,Kawabata K,YoshidaH,HatayamaH, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine among pregnant women: lowered antibody response by prior seasonal vaccination. J Infect Dis (2011) 203(9):1301-8. doi:10.1093/infdis/jir026
62. Healy CM. Vaccines in pregnant women and research initiatives. Clin Obstet Gynecol (2012) 55(2):474-86. doi:10.1097/GRF.0b013e31824f3acb
63. LissauerD,PiperK,GoodyearO,KilbyMD,Moss PA. Fetal-specificCD8+ cyto-toxic T cell responses develop during normal human pregnancy and exhibit broad functional capacity. J Immunol (2012) 189(2):1072-80. doi:10.4049/ jimmunol.1200544
64. Mold JE, McCune JM. At the crossroads between tolerance and aggres-sion: revisiting the "layered immune system" hypothesis. Chimerism (2011) 2(2):35-41. doi:10.4161/chim.2.2.16329
65. Michaelsson J,Mold JE,McCune JM,Nixon DF. Regulation of T cell responses in the developing human fetus. J Immunol (2006) 176(10):5741-8. doi:10. 4049/jimmunol.176.10.5741
66. Mold JE,Michaelsson J, Burt TD,MuenchMO, Beckerman KP, BuschMP, et al. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science (2008) 322(5907):1562-5. doi:10.1126/science.1164511
67. Takahata Y, Nomura A, Takada H, Ohga S, Furuno K, Hikino S, et al. CD25+CD4+ T cells in human cord blood: an immunoregulatory subset with naive phenotype and specific expression of forkhead box p3 (Foxp3) gene. Exp Hematol (2004) 32(7):622-9. doi:10.1016/j.exphem.2004.03.012
68. Mold JE, Venkatasubrahmanyam S, Burt TD, Michaelsson J, Rivera JM, Galk-ina SA, et al. Fetal and adult hematopoietic stem cells give rise to distinct T cell lineages in humans. Science (2010) 330(6011):1695-9. doi:10.1126/science. 1196509
69. Simonetta F, Bourgeois C. CD4+FOXP3+ regulatory T-cell subsets in human immunodeficiency virus infection. Front Immunol (2013) 4:215. doi:10.3389/fimmu.2013.00215
70. ChevalierMF,Weiss L. The split personality of regulatory T cells in HIV infec-tion. Blood (2013) 121(1):29-37. doi:10.1182/blood-2012-07-409755
71. Freguja R, Gianesin K, Mosconi I, Zanchetta M, Carmona F, Rampon O, et al. Regulatory T cells and chronic immune activation in human immun-odeficiency virus 1 (HIV-1)-infected children. Clin Exp Immunol (2011) 164(3):373-80. doi:10.1111/j.1365-2249.2011.04383.x
72. Prendergast A, O'Callaghan M, Menson E, Hamadache D, Walters S, Klein N, et al. Factors influencing T cell activation and programmed death 1 expres-sion inHIV-infected children. AIDS ResHumRetroviruses (2012) 28(5):465-8. doi:10.1089/AID.2011.0113
73. Arguello RJ, Balbaryski J, Barboni G, Candi M, Gaddi E, Laucella S. Altered frequency and phenotype of CD4+ forkhead box protein 3+ T cells and its association with autoantibody production in human immunodeficiency virus-infected paediatric patients. Clin Exp Immunol (2012) 168(2):224-33. doi:10.1111/j.1365-2249.2012.04569.x
74. Legrand FA, Nixon DF, Loo CP, Ono E, Chapman JM, Miyamoto M, et al. Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal. PLoS One (2006) 1:e102. doi:10.1371/journal.pone.0000102
75. Borrow P, Lewicki H,Hahn BH, Shaw GM,OldstoneMB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. JVirol (1994) 68(9):6103-10.
76. Koup RA, Safrit JT,CaoY,Andrews CA,McLeodG,BorkowskyW, et al. Tempo-ral association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 68(7):4650-5.
77. Friedrich TC,Valentine LE,Yant LJ,Rakasz EG, Piaskowski SM, Furlott JR, et al. Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J Virol (2007) 81(7):3465-76. doi:10.1128/JVI.02392-06
78. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lym-phocytes. Science (1999) 283(5403):857-60. doi:10.1126/science.283.5403.857
79. Rodriguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, Kitahata M, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA (2006) 296(12):1498-506. doi:10.1001/jama. 296.12.1498
80. Goulder PJ,Walker BD. HIV and HLA class I: an evolving relationship. Immu-nity (2012) 37(3):426-40. doi:10.1016/j.immuni.2012.09.005
81. Crawford H, Lumm W, Leslie A, Schaefer M, Boeras D, Prado JG, et al. Evo-lution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive indi-viduals and their transmission recipients. J Exp Med (2009) 206(4):909-21. doi:10.1084/jem.20081984
82. Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, et al. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immun-odeficiency virus type 1 replication. J Virol (2007) 81(22):12382-93. doi:10. 1128/JVI.01543-07
83. Prince JL, Claiborne DT, Carlson JM, Schaefer M, Yu T, Lahki S, et al. Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis. PLoS Pathog (2012) 8(11):e1003041. doi:10.1371/journal. ppat.1003041
84. Goepfert PA, Lumm W, Farmer P, Matthews P, Prendergast A, Carlson JM, et al. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med (2008) 205(5):1009-17. doi:10.1084/jem.20072457
85. Thobakgale CF, Prendergast A, Crawford H, Mkhwanazi N, Ramduth D, Reddy S, et al. Impact of HLA in mother and child on disease progression of pediatric human immunodeficiency virus type 1 infection. J Virol (2009) 83(19):10234-44. doi:10.1128/JVI.00921-09
86. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature (2001) 412(6844):334-8. doi:10.1038/35085576
87. Sharp ER,Willberg CB, Kuebler PJ, Abadi J, Fennelly GJ, Dobroszycki J, et al. Immunodominance of HIV-1 specific CD8+ T-cell responses is related to disease progression rate in vertically infected adolescents. PLoS One (2011) 6(7):e21135. doi:10.1371/journal.pone.0021135
88. Haynes BF, Heinly CS. Early human T cell development: analysis of the human thymus at the time of initial entry of hematopoietic stem cells into the fetal thymic microenvironment. J Exp Med (1995) 181(4):1445-58. doi:10.1084/jem.181.4.1445
89. Luzuriaga K, Holmes D, Hereema A,Wong J, Panicali DL, Sullivan JL. HIV-1-specific cytotoxic T lymphocyte responses in the first year of life. J Immunol (1995) 154(1):433-43.
90. Thobakgale CF, Ramduth D, Reddy S, Mkhwanazi N, de Pierres C, Mood-ley E, et al. Human immunodeficiency virus-specific CD8+ T-cell activity is detectable frombirth in themajority of in utero-infected infants. JVirol (2007) 81(23):12775-84. doi:10.1128/JVI.00624-07
91. Scott ZA, Chadwick EG, Gibson LL, Catalina MD, McManus MM, Yogev R, et al. Infrequent detection of HIV-1-specific, but not cytomegalovirus-specific, CD8(+) T cell responses in young HIV-1-infected infants. J Immunol (2001) 167(12):7134-40. doi:10.4049/jimmunol.167.12.7134
92. Shalekoff S, Meddows-Taylor S, Gray GE, Sherman GG, Coovadia AH, Kuhn L, et al. Identification of human immunodeficiency virus-1 specific CD8+ and CD4+ T cell responses in perinatally-infected infants and their mothers. AIDS (2009) 23(7):789-98. doi:10.1097/QAD.0b013e328329c784
93. Lohman BL, Slyker JA, Richardson BA, Farquhar C, Mabuka JM, Crudder C, et al. Longitudinal assessment of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon responses during the first year of life in HIV-1-infected infants. J Virol (2005) 79(13):8121-30. doi:10.1128/JVI.79.13.8121-8130.2005
94. Nqoko B, Day CL, Mansoor N, De Kock M, Hughes EJ, Hawkridge T, et al. HIV-specific gag responses in early infancy correlate with clinical outcome and inversely with viral load. AIDS Res Hum Retroviruses (2011) 27(12):1311-6. doi:10.1089/aid.2011.0081
95. Huang S, Dunkley-Thompson J, Tang Y, Macklin EA, Steel-Duncan J, Singh-Minott I, et al. Deficiency of HIV-Gag-specific T cells in early childhood correlates with poor viral containment. J Immunol (2008) 181(11):8103-11. doi:10.4049/jimmunol.181.11.8103
96. Prendergast A, Goodliffe H, Clapson M, Cross R, Tudor-Williams G, Rid-dell A, et al. Gag-specific CD4+ T-cell responses are associated with viro-logical control of paediatric HIV-1 infection. AIDS (2011) 25(10):1329-31. doi:10.1097/QAD.0b013e3283478575
97. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8+ T-cell responses to different HIV proteins have discor-dant associations with viral load. Nat Med (2007) 13(1):46-53. doi:10.1038/ nm1520
98. Geldmacher C, Currier JR, Herrmann E, Haule A, Kuta E,McCutchan F, et al. CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immun-odeficiency virus type 1-seropositive patients. J Virol (2007) 81(5):2440-8. doi:10.1128/JVI.01847-06
99. Akinsiku OT, Bansal A, Sabbaj S, Heath SL, Goepfert PA. Interleukin-2 pro-duction by polyfunctional HIV-1-specific CD8 T cells is associated with enhanced viral suppression. J Acquir ImmuneDefic Syndr (2011) 58(2):132-40. doi:10.1097/QAI.0b013e318224d2e9
100. BettsMR,NasonMC,West SM,De Rosa SC,Migueles SA,AbrahamJ, et al.HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 107(12):4781-9. doi:10.1182/blood-2005-12-4818
101. Thobakgale CF, Streeck H,Mkhwanazi N,Mncube Z,Maphumulo L, Chonco F, et al. Short communication: CD8(+) T cell polyfunctionality profiles in pro-gressive and nonprogressive pediatric HIV type 1 infection. AIDS Res Hum Retroviruses (2011) 27(9):1005-12. doi:10.1089/AID.2010.0227
102. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, et al.HIV-specific CD8+ T cell proliferation is coupled to perforin expres-sion and is maintained in nonprogressors. Nat Immunol (2002) 3(11):1061-8. doi:10.1038/ni845
103. Grakoui A, Shoukry NH,Woollard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science (2003) 302(5645):659-62. doi:10.1126/science.1088774
104. Lichterfeld M, Kaufmann DE, Yu XG,Mui SK, Addo MM, Johnston MN, et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med (2004) 200(6):701-12. doi:10.1084/jem.20041270
105. ShedlockDJ, ShenH. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science (2003) 300(5617):337-9. doi:10.1126/science. 1082305
106. Sun JC,BevanMJ.DefectiveCD8Tcellmemory following acute infectionwith-out CD4 T cell help. Science (2003) 300(5617):339-42. doi:10.1126/science. 1083317
107. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol (2003) 77(21):11708-17. doi:10.1128/JVI.77.21.11708-11717.2003
108. Mattapallil JJ,Douek DC,Hill B,Nishimura Y,MartinM, RoedererM.Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature (2005) 434(7037):1093-7. doi:10.1038/nature03501
109. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 417(6884):95-8. doi:10.1038/417095a
110. Streeck H, D'Souza MP, Littman DR, Crotty S. Harnessing CD4(+) T cell responses in HIV vaccine development. Nat Med (2013) 19(2):143-9. doi:10. 1038/nm.3054
111. Chevalier MF, Julg B, Pyo A, Flanders M, Ranasinghe S, Soghoian DZ, et al. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol (2011) 85(2):733-41. doi:10.1128/JVI.02030-10
112. Norris PJ, Moffett HF, Yang OO, Kaufmann DE, Clark MJ, Addo MM, et al. Beyond help: direct effector functions of human immunodeficiency virus type 1-specific CD4(+) T cells. J Virol (2004) 78(16):8844-51. doi:10.1128/JVI.78. 16.8844-8851.2004
113. Soghoian DZ, Streeck H. Cytolytic CD4(+) T cells in viral immunity. Expert Rev Vaccines (2010) 9(12):1453-63. doi:10.1586/erv.10.132
114. Soghoian DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Per-tel T, et al. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med (2012) 4(123):123ra25. doi:10.1126/scitranslmed.3003165
115. Ranasinghe S, Flanders M, Cutler S, Soghoian DZ, Ghebremichael M, Davis I, et al. HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J Virol (2012) 86(1):277-83. doi:10.1128/JVI.05577-11
116. Ramduth D, Day CL, Thobakgale CF, Mkhwanazi NP, de Pierres C, Reddy S, et al. Immunodominant HIV-1 Cd4+ T cell epitopes in chronic untreated clade C HIV-1 infection. PLoS One (2009) 4(4):e5013. doi:10.1371/journal. pone.0005013
117. Barrios C, Brandt C, Berney M, Lambert PH, Siegrist CA. Partial correction of the TH2/TH1 imbalance in neonatal murine responses to vaccine anti-gens through selective adjuvant effects. Eur J Immunol (1996) 26(11):2666-70. doi:10.1002/eji.1830261118
118. Prescott SL, Macaubas C, Holt BJ, Smallacombe TB, Loh R, Sly PD, et al. Transplacental priming of the human immune system to environmental aller-gens: universal skewing of initial T cell responses toward the Th2 cytokine profile. J Immunol (1998) 160(10):4730-7.
119. Adkins B, Bu Y, Guevara P. The generation of Th memory in neonates ver-sus adults: prolonged primary Th2 effector function and impaired develop-ment of Th1 memory effector function in murine neonates. J Immunol (2001) 166(2):918-25. doi:10.4049/jimmunol.166.2.918
120. Upham JW, Lee PT, Holt BJ, Heaton T, Prescott SL, Sharp MJ, et al. Devel-opment of interleukin-12-producing capacity throughout childhood. Infect Immun (2002) 70(12):6583-8. doi:10.1128/IAI.70.12.6583-6588.2002
121. Cleary AM, Tu W, Enright A, Giffon T, Dewaal-Malefyt R, Gutierrez K, et al. Impaired accumulation and function of memory CD4 T cells in human IL-12 receptor beta 1 deficiency. J Immunol (2003) 170(1):597-603. doi:10.4049/ jimmunol.170.1.597
122. Yap G, Pesin M, Sher A. Cutting edge: IL-12 is required for the maintenance of IFN-gamma production in T cells mediating chronic resistance to the intracellular pathogen, Toxoplasma gondii. J Immunol (2000) 165(2):628-31. doi:10.4049/jimmunol.165.2.628
123. Zhang X, Mozeleski B, Lemoine S, Deriaud E, Lim A, Zhivaki D, et al. CD4 T cells with effector memory phenotype and function develop in the sterile environment of the fetus. Sci Transl Med (2014) 6(238):238ra72. doi:10.1126/scitranslmed.3008748
124. Ramduth D, Thobakgale CF, Mkhwanazi NP, De Pierres C, Reddy S, van der Stok M, et al. Detection of HIV type 1 gag-specific CD4(+) T cell responses in acutely infected infants. AIDS Res Hum Retroviruses (2008) 24(2):265-70. doi:10.1089/aid.2007.0096
125. Hartigan-O'Connor DJ, Abel K, McCune JM. Suppression of SIV-specific CD4+ T cells by infant but not adult macaque regulatory T cells: impli-cations for SIV disease progression. J Exp Med (2007) 204(11):2679-92. doi:10.1084/jem.20071068
126. Imami N, Westrop SJ, Grageda N, Herasimtschuk AA. Long-term non-progression and broad HIV-1-specific proliferative T-cell responses. Front Immunol (2013) 4:58. doi:10.3389/fimmu.2013.00058
127. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 278(5342):1447-50. doi:10.1126/science.278.5342. 1447
128. McNeil AC, Shupert WL, Iyasere CA, Hallahan CW, Mican JA, Davey RT Jr., et al. High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc Natl Acad Sci USA (2001) 98(24):13878-83. doi:10.1073/ pnas.251539598
129. Boaz MJ,Waters A,Murad S, Easterbrook PJ, Vyakarnam A. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol (2002) 169(11):6376-85. doi:10.4049/jimmunol.169.11.6376
130. Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol (2005) 79(22):14169-78. doi:10.1128/JVI.79. 22.14169-14178.2005
131. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity (2013) 38(1):13-25. doi:10.1016/j.immuni.2013.01.004
132. Scott ZA, Beaumier CM, Sharkey M, Stevenson M, Luzuriaga K. HIV-1 repli-cation increases HIV-specific CD4+ T cell frequencies but limits proliferative capacity in chronically infected children. J Immunol (2003) 170(11):5786-92. doi:10.4049/jimmunol.170.11.5786
133. Feeney ME, Draenert R, Roosevelt KA, Pelton SI, McIntosh K, Burchett SK, et al. Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection. J Immunol (2003) 171(12):6968-75. doi:10.4049/jimmunol. 171.12.6968
134. Kuhn L,Meddows-Taylor S, Gray G, Tiemessen C. Human immunodeficiency virus (HIV)-specific cellular immune responses in newborns exposed to HIV in utero. Clin Infect Dis (2002) 34(2):267-76. doi:10.1086/338153
135. Barber DL,Wherry EJ,Masopust D, Zhu B,Allison JP, Sharpe AH, et al. Restor-ing function in exhausted CD8 T cells during chronic viral infection. Nature (2006) 439(7077):682-7. doi:10.1038/nature04444
136. Day CL, Kaufmann DE, Kiepiela P, Brown JA,Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.Nature (2006) 443(7109):350-4. doi:10.1038/nature05115
137. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med (2008) 205(12):2763-79. doi:10.1084/jem.20081398
138. Peretz Y,He Z, Shi Y,Yassine-Diab B,Goulet JP, Bordi R, et al. CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. PLoS Pathog (2012) 8(8):e1002840. doi:10.1371/journal.ppat. 1002840
139. Blackburn SD, ShinH,HainingWN,Zou T,WorkmanCJ,PolleyA, et al.Coreg-ulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol (2009) 10(1):29-37. doi:10.1038/ni.1679
140. Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, et al.Upregulation of CTLA-4 byHIV-specificCD4+ T cells correlateswith dis-ease progression and defines a reversible immune dysfunction. Nat Immunol (2007) 8(11):1246-54. doi:10.1038/ni1515
141. Zhang JY, Zhang Z, Wang X, Fu JL, Yao J, Jiao Y, et al. PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical pro-gressors but not in long-term nonprogressors. Blood (2007) 109(11):4671-8. doi:10.1182/blood-2006-09-044826
142. Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling mol-ecules for immune modulation. Nat Rev Drug Dis (2013) 12(2):130-46. doi:10.1038/nrd3877
143. Porichis F, Kaufmann DE. HIV-specific CD4 T cells and immune control of viral replication. Curr Opin HIV AIDS (2011) 6(3):174-80. doi:10.1097/COH. 0b013e3283454058
144. Tandon R, Giret MT, Sengupta D, York VA, Wiznia AA, Rosenberg MG, et al. Age-related expansion of Tim-3 expressing T cells in vertically HIV-1 infected children. PLoS One (2012) 7(9):e45733. doi:10.1371/journal.pone.0045733
145. Kuller LH, Tracy R, BellosoW,DeWit S,Drummond F, Lane HC, et al. Inflam-matory and coagulation biomarkers and mortality in patients with HIV infec-tion. PLoS Med (2008) 5(10):e203. doi:10.1371/journal.pmed.0050203
146. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis (2009) 200(6):973-83. doi:10.1086/605447
147. Serrano-Villar S,Gutierrez C,VallejoA,Hernandez-Novoa B,Diaz L,Abad Fer-nandezM, et al. The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect (2013) 66(1):57-66. doi:10.1016/j.jinf.2012.09.013
148. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narvaez AB, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood (2004) 104(4):942-7. doi:10. 1182/blood-2003-09-3333
149. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS (2003) 17(13):1881-8. doi:10.1097/00002030-200309050-00006
150. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature (2014) 505(7484):509-14. doi:10.1038/nature12940
151. Monroe KM, Yang Z, Johnson JR, Geng X, Doitsh G, Krogan NJ, et al. IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science (2014) 343(6169):428-32. doi:10.1126/science.1243640
152. Giorgi JV, Hultin LE,McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection ismore closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J InfectDis (1999) 179(4):859-70. doi:10.1086/314660
153. Paul ME,Mao C, Charurat M, Serchuck L, Foca M, Hayani K, et al. Predictors of immunologic long-term nonprogression in HIV-infected children: impli-cations for initiating therapy. J Allergy Clin Immunol (2005) 115(4):848-55. doi:10.1016/j.jaci.2004.11.054
154. Ssewanyana I, Baker CA, Ruel T, Bousheri S, Kamya M, Dorsey G, et al. The distribution and immune profile of T cell subsets in HIV-infected children from Uganda. AIDS Res Hum Retroviruses (2009) 25(1):65-71. doi:10.1089/ aid.2008.0138
155. Chahroudi A, Bosinger SE, Vanderford TH, Paiardini M, Silvestri G. Nat-ural SIV hosts: showing AIDS the door. Science (2012) 335(6073):1188-93. doi:10.1126/science.1217550
156. Silvestri G, Sodora DL, Koup RA, Paiardini M, O'Neil SP, McClure HM, et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by lim-ited bystander immunopathology despite chronic high-level viremia. Immunity (2003) 18(3):441-52. doi:10.1016/S1074-7613(03)00060-8
157. Bosinger SE, Li Q, Gordon SN, Klatt NR, Duan L, Xu L, et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest (2009) 119(12):3556-72. doi:10.1172/ JCI40115
158. Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, et al. Val-ganciclovir reduces T cell activation in HIV-infected individuals with incom-plete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis (2011) 203(10):1474-83. doi:10.1093/infdis/jir060
159. Sauce D, Larsen M, Fastenackels S, Pauchard M, Ait-Mohand H, Schneider L, et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood (2011) 117(19):5142-51. doi:10.1182/blood-2011-01-331306
160. Lederman MM, Calabrese L, Funderburg NT, Clagett B, Medvik K, Bonilla H, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis (2011) 204(8):1217-26. doi:10.1093/infdis/jir507
161. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev (2013) 254(1):326-42. doi:10.1111/imr.12065
162. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious dis-eases other than AIDS. AIDS (2008) 22(18):2409-18. doi:10.1097/QAD. 0b013e3283174636
163. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al. CD4+ T cell depletion during all stages of HIV disease occurs pre-dominantly in the gastrointestinal tract. J Exp Med (2004) 200(6):749-59. doi:10.1084/jem.20040874
164. Xu H, Wang X, Liu DX, Moroney-Rasmussen T, Lackner AA, Veazey RS. IL-17-producing innate lymphoid cells are restricted to mucosal tissues and are depleted in SIV-infected macaques. Mucosal Immunol (2012) 5(6):658-69. doi:10.1038/mi.2012.39
165. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol (2013) 21(1):6-13. doi:10.1016/ j.tim.2012.09.001
166. Brenchley JM,PriceDA, Schacker TW,Asher TE, SilvestriG,Rao S, et al.Micro-bial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 12(12):1365-71. doi:10.1038/nm1511
167. Paiardini M. Th17 cells in natural SIV hosts. Curr Opin HIV AIDS (2010) 5(2):166-72. doi:10.1097/COH.0b013e328335c161
168. Abad-Fernandez M, Vallejo A, Hernandez-Novoa B, Diaz L, Gutierrez C, Madrid N, et al. Correlation between different methods to measure micro-bial translocation and its association with immune activation in long-term suppressed HIV-1-infected individuals. J Acquir Immune Defic Syndr (2013) 64(2):149-53. doi:10.1097/QAI.0b013e31829a2f12
169. Sherman MP. New concepts of microbial translocation in the neonatal intestine: mechanisms and prevention. Clin Perinatol (2010) 37(3):565-79. doi:10.1016/j.clp.2010.05.006
170. Fanaro S, Chierici R, Guerrini P, Vigi V. Intestinal microflora in early infancy: composition and development. Acta Paediatr (2003) 91(441):48-55. doi:10.1111/j.1651-2227.2003.tb00646.x
171. Kourtis AP, Ibegbu CC,Wiener J, King CC, Tegha G, Kamwendo D, et al. Role of intestinal mucosal integrity in HIV transmission to infants through breast-feeding: the BAN study. J Infect Dis (2013) 208(4):653-61. doi:10.1093/infdis/ jit221
172. Wallet MA, Rodriguez CA, Yin L, Saporta S, Chinratanapisit S, Hou W, et al. Microbial translocation induces persistent macrophage activation unre-lated to HIV-1 levels or T-cell activation following therapy. AIDS (2010) 24(9):1281-90. doi:10.1097/QAD.0b013e328339e228
173. Papasavvas E, Azzoni L, Foulkes A, Violari A, Cotton MF, Pistilli M, et al. Increased microbial translocation in
174. Pilakka-Kanthikeel S, Huang S, Fenton T, Borkowsky W, Cunningham CK, Pahwa S. Increased gut microbial translocation in HIV-infected children per-sists in virologic responders and virologic failures after antiretroviral therapy. Pediatr Infect Dis J (2012) 31(6):583-91. doi:10.1097/INF.0b013e31824da0f5
175. Pilakka-Kanthikeel S,KrisA,SelvarajA,Swaminathan S,Pahwa S. Immune acti-vation is associated with increased gut microbial translocation in treatment-naive, HIV-infected children in a resource-limited setting. J Acquir Immune Defic Syndr (2014) 66(1):16-24. doi:10.1097/QAI.0000000000000096
176. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.NEngl JMed (2009) 361(23):2209-20. doi:10.1056/NEJMoa0908492
177. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 366(14):1275-86. doi:10.1056/NEJMoa1113425
178. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol (2002) 2(9):706-13. doi:10.1038/nri891
179. Walker BD, Burton DR. Toward an AIDS vaccine. Science (2008) 320(5877):760-4. doi:10.1126/science.1152622
180. Sather DN, Armann J, Ching LK,Mavrantoni A, Sellhorn G, Caldwell Z, et al. Factors associated with the development of cross-reactive neutralizing anti-bodies during human immunodeficiency virus type 1 infection. J Virol (2009) 83(2):757-69. doi:10.1128/JVI.02036-08
181. Walker LM,HuberM,Doores KJ, Falkowska E, Pejchal R, Julien JP, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 477(7365):466-70. doi:10.1038/nature10373
182. Gray ES, Madiga MC, Hermanus T, Moore PL,Wibmer CK, Tumba NL, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol (2011) 85(10):4828-40. doi:10.1128/JVI.00198-11
183. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. Rational design of envelope identifies broadly neutralizing humanmonoclonal antibod-ies to HIV-1. Science (2010) 329(5993):856-61. doi:10.1126/science.1187659
184. Goo L, Chohan V, Nduati R, Overbaugh J. Early development of broadly neu-tralizing antibodies in HIV-1-infected infants. Nat Med (2014) 20(6):655-8. doi:10.1038/nm.3565
185. Siegrist CA. Neonatal and early life vaccinology. Vaccine (2001) 19(25-26):3331-46. doi:10.1016/S0264-410X(01)00028-7
186. Piantadosi A, Panteleeff D, Blish CA, Baeten JM, JaokoW,McClelland RS, et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol (2009) 83(19):10269-74. doi:10.1128/JVI.01149-09
187. ScharfO,GoldingH,King LR,EllerN,FrazierD,Golding B, et al. Immunoglob-ulin G3 frompolyclonal human immunodeficiency virus (HIV) immune glob-ulin is more potent than other subclasses in neutralizing HIV type 1. J Virol (2001) 75(14):6558-65. doi:10.1128/JVI.75.14.6558-6565.2001
188. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med (2000) 6(2):200-6. doi:10.1038/72309
189. Lafeuillade A. Eliminating the HIV reservoir. Curr HIV/AIDS Rep (2012) 9(2):121-31. doi:10.1007/s11904-012-0115-y
190. PaceMJ, Agosto L, Graf EH, O'Doherty U. HIV reservoirs and latency models. Virology (2011) 411(2):344-54. doi:10.1016/j.virol.2010.12.041
191. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al.HIV reservoir size and persistence are driven by T cell survival and home-ostatic proliferation. Nat Med (2009) 15(8):893-900. doi:10.1038/nm.1972
192. Persaud D, Palumbo PE, Ziemniak C, Hughes MD, Alvero CG, Luzuriaga K, et al. Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS (2012) 26(12):1483-90. doi:10.1097/QAD.0b013e3283553638
193. Ananworanich J, Puthanakit T, Suntarattiwong P, Chokephaibulkit K, Kerr SJ, Fromentin R, et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS (2014) 28(7):1015-20. doi:10.1097/QAD.0000000000000178
194. Luzuriaga K, Tabak B, Garber M, Chen YH, Ziemniak C,McManus MM, et al. Reduced HIV reservoirs after early treatment HIV-1 proviral reservoirs decay continuously under sustained virologic control in early-treatedHIV-1-infected children. J Infect Dis (2014). doi:10.1093/infdis/jiu297
195. Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-treatment HIV-1 controllers with a long-term viro-logical remission after the interruption of early initiated antiretroviral ther-apy ANRS VISCONTI Study. PLoS Pathog (2013) 9(3):e1003211. doi:10.1371/ journal.ppat.1003211
196. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell (2013) 155(3):540-51. doi:10.1016/j.cell.2013.09. 020
197. Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantita-tion of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol (2005) 304:3-15. doi:10.1385/1-59259-907-9:003
198. Laird GM, Eisele EE, Rabi SA, Lai J, Chioma S, Blankson JN, et al. Rapid quan-tification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog (2013) 9(5):e1003398. doi:10.1371/journal.ppat.1003398
199. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term anti-retroviral therapy. J Infect Dis (2008) 197(5):714-20. doi:10.1086/527324
200. Yukl SA,Gianella S, Sinclair E, Epling L, Li Q,Duan L, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiv-ing suppressive antiretroviral therapy. J Infect Dis (2010) 202(10):1553-61. doi:10.1086/656722
201. Descours B, Avettand-Fenoel V, Blanc C, Samri A, Melard A, Supervie V, et al. Immune responses driven by protective human leukocyte antigen alle-les from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clin Infect Dis (2012) 54(10):1495-503. doi:10.1093/cid/cis188
202. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, et al. Stim-ulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity (2012) 36(3):491-501. doi:10.1016/j.immuni.2012.01.014